|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2004-3-25
|
|
pubmed:abstractText |
MUC-1/DF-3 remains an attractive target for vaccine therapy. It is overexpressed in the majority of human carcinomas and multiple myeloma. Clinical trials using MUC-1-based vaccines have demonstrated safety, clinical responses, and the induction of T-cell responses directed against MUC-1. Previous studies in experimental models and in clinical trials have demonstrated that altering the amino acid sequence of a "self" epitope can lead to the generation of an enhancer agonist epitope capable of eliciting stronger T-cell responses than the native epitope can.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2139-49
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:15041735-Amino Acid Sequence,
pubmed-meshheading:15041735-Breast Neoplasms,
pubmed-meshheading:15041735-Cancer Vaccines,
pubmed-meshheading:15041735-Cell Line, Tumor,
pubmed-meshheading:15041735-Consensus Sequence,
pubmed-meshheading:15041735-Dendritic Cells,
pubmed-meshheading:15041735-Epitopes,
pubmed-meshheading:15041735-Female,
pubmed-meshheading:15041735-Flow Cytometry,
pubmed-meshheading:15041735-HLA-A2 Antigen,
pubmed-meshheading:15041735-Humans,
pubmed-meshheading:15041735-Interferon-gamma,
pubmed-meshheading:15041735-Interleukins,
pubmed-meshheading:15041735-Lymphocyte Activation,
pubmed-meshheading:15041735-Melanoma,
pubmed-meshheading:15041735-Mucin-1,
pubmed-meshheading:15041735-Peptide Fragments,
pubmed-meshheading:15041735-T-Lymphocytes,
pubmed-meshheading:15041735-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:15041735-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.
|
|
pubmed:affiliation |
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.
|
|
pubmed:publicationType |
Journal Article
|
